background: The roles of cell proliferation and genomic instability in endometriosis are highly debated aspects of the pathogenesis of this disease. Aurora A and B kinases play different important roles in cell cycle control and genomic instability and have never been studied in endometriosis. The aim of this study was to compare the expression levels of Aurora kinases, Ki-67 and hormone receptor in endometriotic tissue (ET) and normal endometrium.
Introduction
Endometriosis is characterized by the presence of endometrial-like tissue outside the uterus, causing pelvic pain and infertility in 5-10% of reproductive-aged women (Olive and Schwartz, 1993; Eskenazi and Warner, 1997; Giudice and Kao, 2004; Bulun, 2009) . It is thought to be principally caused by the shedding of viable endometrial cells into the peritoneal cavity by retrograde menstruation followed by implantation and growth of these cells on the surface of pelvic organs (Sampson, 1927) .
The pathogenesis of endometriosis remains poorly understood, and it is unclear why ectopic endometrial growth occurs only in a subset of women when retrograde menstruation and the presence of viable endometrial cells in peritoneal fluid is observed in 80% of women of reproductive age (Halme et al., 1984; Kruitwagen et al., 1991) . One of the most debated aspects of the pathogenesis of this disease is the deregulation of the cell cycle, which could be one of the survival mechanisms of ectopic endometrium out of the uterus. Aurora A kinase, also known as serine/threonine-protein kinase 6, is a member of a family of mitotic serine/threonine kinases. It has been implicated in the assembly of the mitotic spindle and is indispensable for chromatin segregation and subsequent passage into the mitotic phase (Katayama et al., 2003) . Aurora A kinase is primarily localized to the centrosomes from the beginning of the centrosome duplication until the dividing cell exits from mitosis (G2 phase to M phase of the cell cycle) (Karthigeyan et al., 2010) . This kinase is a key regulatory component of the p53 pathway and its overexpression leads to increased p53 degradation (Katayama et al., 2004) . Moreover, recent literature suggests the p53 pathway is related to endometriosis because increased transcription of p53 has been observed in endometriotic tissues (ETs) (Zubor et al., 2009) .
Aurora B kinase is a protein that functions in the attachment of the mitotic spindle to the centromere and, consequently, is also important in chromosomal segregation during mitosis. It is localized on the centromeres (kinetochores) from prophase through the metaphase-anaphase transition (Kelly et al., 2010; Wang et al., 2010) . Aurora A and B kinase overexpression could contribute to genetic instability, possibly due to defects in mitotic progression (Ke et al., 2003; Chu et al., 2010) . In the literature, it has been suggested that genomic instability is a feature of endometriosis (Gogusev et al., 1999; Bischoff et al., 2002) .
Tissue microarray (TMA) models represent an increasingly useful means of understanding the clinical impact of diagnostic-, prognosticand therapy-related markers (Hassan et al., 2008) , and the use of TMAs has already been validated for endometriosis (Kamat et al., 2004) .
The aim of our study was to analyse the expression of Aurora kinase family proteins in ETs and normal endometrium. Additionally, we analysed the expression of Ki-67 (a proliferation marker) and hormone receptors to validate our TMA model.
Materials and Methods

Patients and specimens
From the registry of the Pathology Department of the University Hospital of Udine, a total of 220 women who had a histopathological diagnosis of endometriosis between January 2000 and December 2009 were identified. Among these 220 women, 194 met the following inclusion criteria. We included all Caucasian women of reproductive age at the time of intervention, who had not taken any hormone therapy during the year before surgery. We excluded eight women from our analysis because of menopause or climacteric and 18 because of they used hormone therapy during the year before surgery.
A total of 438 paraffin blocks containing ET were available from these 194 women. For every block, we obtained one core biopsy from formalinfixed paraffin-embedded ET with representative stromal and glandular components. For 15 of the 194 women, 64 core biopsies (obtained from 64 blocks) were available from both ovarian (33 core biopsies) and non-ovarian (31 core biopsies) locations (the non-ovarian group included pelvic non-ovarian ET, non-pelvic ET and bowel ET). According to the date of menses at the time of surgery, all patients were in the follicular or luteal phases (Table I) .
Eutopic endometrial tissue was obtained from formalin-fixed paraffin-embedded uterine tissues from all women who underwent hysterectomy for leiomyoma during the period from 2008 to 2009 and met the following inclusion criteria: Caucasian women of reproductive age at the time of intervention with regular menses and without known endometrial pathology (polyps, dysfunctional uterine bleeding), histological diagnosis of 33% (63/194) adenomyosis, or use of any hormone medication during the year before surgery. We obtained 28 eutopic endometrial core biopsies from 28 women. According to the date of menses and histological confirmation based on Noyes criteria (Noyes et al., 1950) , among these women, 11 were in the follicular phase (proliferative endometrium) and 17 in the luteal phase (secretory endometrium).
The clinical history and data about the surgical intervention for each patient were gathered using the hospital's digital information system (G2). Data included the age at the time of intervention, the date of intervention, the contingent assumption of pre-operative hormone therapy, the localization and staging according to the American Society of Reproductive Medicine (ASRM) classification of endometriosis (ASRM, 1997), parity, gravidity, last menses before intervention and indication for surgery. This study was conducted according to the declaration of Helsinki, and after internal review board approval.
Preparation of TMA slides
Haematoxylin -eosin (H and E) stained sections were carefully examined to select representative regions from each selected donor block. TMAs were made using a Beecher tissue micro-arrayer. A cylindrical, thin-walled needle (inner diameter of 1.5 mm) was used for coring tissues and for transferring cored samples into array cavities in the recipient block.
From the recipient block, we obtained 4-mm-thick transverse sections. These sections were placed on a glass slide and stained. A total of six sections were used for this study. The presence of both glandular and stromal components in ET or in the normal endometrium was verified on H and E sections of the TMA. Even if we experienced loss of superficial implants in the deeper sections, if loss was at the sixth section, 91% of the samples were still accurately evaluable.
Immunohistochemical analysis for Aurora A and Aurora B was conducted as has previously been reported (Kurai et al., 2005; Burum-Auensen et al., 2007) . Briefly, to detect Aurora B expression, citrate buffer retrieval solution, pH 6 (S1700, Dako) was used for antigen retrieval. The slides were incubated overnight with a polyclonal antibody against Aurora B (Abcam, ab2254; Cambridge, UK) at a dilution of 1:400. For Aurora A, Tris -EDTA antigen retrieval buffer, pH 9.0, was used, and the TMA slides were incubated at room temperature for 1 h with monoclonal Aurora A NCL-L-AK2 (Novocastra) at a dilution of 1:50.
To validate the TMA model, the expression of the proliferation marker Ki-67 (M7240, Dako) was also analysed as were the expression levels of the estrogen (ER-XRS100I, Aczon) and progesterone receptors (M3569, Dako).
Semiquantitative analysis of the immunohistochemical staining was conducted independently by two pathologists, and glands were considered separately from stroma for all markers. The number of positive cells was obtained by counting a minimum of 500 stromal cells or 100 epithelial cells. The staining of both the nucleus and the cytoplasm was considered for Aurora A, but only nuclear staining was considered for the other markers (Burum-Auensen et al., 2007) . Staining was semiquantitatively evaluated as follows: percentage of positive cells, intensity of the positivity and H-score (product of percentage of positivity and intensity).
Statistical analysis
Data were analysed using R (version 2.10.1), and P , 0.05 was considered significant. For all proteins analysed, the staining was investigated in terms of percentage of cells positive for a marker per slide, the H-score and the percentage of positive samples. The normality of variables was evaluated using the Kolmogorov-Smirnov test. Non-parametric data were presented as the median value and the interquartile range (IQR), whereas parametric data were described with the mean value and the standard deviation.
The Kruskal -Wallis test and one-way analysis of variance for continuous variables were used for the variance analysis where appropriate. For comparison of multiple categorical variables, the x 2 test was used. For bivariate analysis, the following statistical tests were applied: the Wilcoxon's test and the t-test for continuous variables and the x 2 and Fisher exact tests for categorical variables. Because of the statistically significant age difference between cases and controls, it was necessary to evaluate the results, by dividing the patients into two age groups (,39 years and ≥39 years). In addition, a monovariate and multivariate logistic regression analysis (with age correction) was carried out. Therefore, the prevalence of the H-score over the third centile of the distribution for the hormone receptors was considered as a dependent variable. Meanwhile, the prevalence of the values over the median of the distribution for Aurora A, Aurora B kinase (H-score) and Ki-67 (positivity) were considered as dependent variables.
In cases where both ovarian and non-ovarian locations were observed in the same woman, an analysis with the Wilcoxon test for paired variables was carried out. The median value of ovarian and non-ovarian samples of every patient were taken into consideration and then compared with the paired Wilcoxon test.
Results
General description
The mean population age at surgical intervention was 39 years (+9), and the mean storage time of samples was 5 years (+3). Patients affected by endometriosis were significantly younger at the time of surgery (39 + 9 years) than healthy control women (43 + 6 years; P , 0.05). A total of 61% (17/28) of controls were in the luteal phase (secretory endometrium), while the remaining 39% of women were in the follicular phase (proliferative endometrium).
Based on last menses date, 56% of patients with endometriosis underwent surgery during the follicular phase. We did not find any significant difference between the protein expression profiles of ETs removed during the follicular phase versus those removed during the luteal phase.
The ovary was the most common endometriosis location with 81% of cases (353/438), followed by the pelvis with 11% (48/438), extrapelvic locations with 5% (24/438) and the bowel with 3% (13/438). Table I shows the distribution of ETs according to the ASRM stage/ severity staging of abdominal disease; more than 50% of patients were affected by stage III or IV disease.
In our samples, the presence of an ovarian mass was the most common indication for surgery, and the second most common indication was the presence of chronic pelvic pain.
When comparing the protein expression among the different endometriosis locations, the normal secretory endometrium and the proliferative endometrium, no remarkable difference emerged between the non-ovarian locations; however, a significant difference was observed between ovarian and non-ovarian locations as well as between the secretory and the proliferative endometrium. Based on these preliminary observations, the samples were divided into four groups: ovarian localization, non-ovarian localization, proliferative endometrium and secretory endometrium.
Estrogen and progesterone receptors
As shown in Fig. 1 , we observed some expected differences between proliferative and secretory endometrium. Tables II and III show that the estrogen and progesterone receptor H-score values were lower in ovarian ETs than in all other tissue types, in both the glandular and the stromal component (P , 0.05), except for estrogen receptor H-score values in the stromal component of secretory endometrium, progesterone receptor H-score values in the glandular component of secretory endometrium and progesterone receptor H-score values in the stroma of non-ovarian ETs. These differences remained evident even after the age correction. Moreover, the hormone receptor H-scores in the non-ovarian locations seemed to be lower than in the proliferative endometrium (P ¼ n.s.). In ovarian ETs, the hormone receptor H-scores in the glandular component were significantly lower than in the stromal component (P , 0.05). In non-ovarian ETs and in proliferative endometrium, the estrogen receptor H-scores in the glandular component were higher than in the stroma (P , 0.05). In secretory endometrium, the progesterone receptor H-scores in the glands were significantly lower than in the stroma (P , 0.05). Finally, the estrogen receptor gland H-score/stroma H-score ratio in ovarian ETs (0.7, IQR 0.2 -1.2) was inverted and significantly lower than in the non-ovarian ETs (1.5, IQR 1.0 -3.0; P , 0.05) (Fig. 1A) . The ovarian ETs progesterone receptor gland H-score/stroma H-score ratio was lower than all other ratios, but the difference was significant only compared with non-ovarian ETs (0.2, IQR 0.1-0.7 versus 0.9 IQR 0.5 -1.0).
Aurora A kinase
Table IV presents the data on Aurora A kinase expression, which was higher in both the glandular and stromal components in the proliferative endometrium than in the ovarian or non-ovarian ETs and in the secretory endometrium, even after age correction. This difference was statistically significant only for the nuclear localization of Aurora A (P , 0.05).
Aurora A kinase was expressed in most samples of proliferative endometrium but only in a minority of samples of ovarian ET, nonovarian ET and secretory endometrium, with a statistically significant difference between the first group and each of the other three groups (P , 0.05).
Selecting only samples expressing Aurora A kinase, lower expression was found in the nucleus of both the glandular and stromal components of ETs than in the normal endometrium (,10% cells/slide). In the glandular cytoplasm, Aurora A was expressed at a higher level in ovarian (55, IQR 22-97) and nonovarian ETs (55, IQR 22 -67) than in the proliferative endometrium (9, IQR 6-15) (P , 0.05) (Fig. 2) , whereas in the stromal cytoplasm, we observed higher H-score values in non-ovarian ET (145, IQR 142-147) than in ovarian ET (6, IQR 5-17) and proliferative endometrium (4, IQR 3 -7) (P , 0.05).
Aurora B kinase and Ki-67
Aurora B kinase and Ki-67 (Table IV ) were expressed at a higher level in the proliferative endometrium than in the ovarian or non-ovarian ETs (P , 0.05) and in the secretory endometrium, even after age correction (P , 0.05). These markers were also higher in non-ovarian than ovarian ETs in monovariate logistic regression and also in multivariate analysis with age correction, as shown in Fig. 3 .
In addition, both Aurora B kinase and Ki-67 were expressed at higher levels than Aurora A kinase in ovarian and non-ovarian ETs and in secretory endometrium. There was a positive correlation among the expression levels of Aurora A and B kinases and Ki-67 in Expression patterns of Aurora A and B kinases the glandular and stromal components of the same specimens (P , 0.05). Because the expression rates of Ki-67 in the glandular and stroma components were not significantly different (P ¼ n.s.), only data relative to the glandular component are reported in Tables II and IV and  Table V and Fig. 3 .
Paired analysis of ovarian and non-ovarian ETs
When analysing the difference in protein expression between ovarian and non-ovarian specimens in the 15 patients with simultaneous multiple endometriosis locations, hormone receptors were expressed at lower levels in the ovarian than in the non-ovarian locations (Table V) with more evidence of differences in expression in the glandular component (P , 0.05) than in the stromal component (P ¼ n.s.).
Aurora A and B kinases and Ki-67 were expressed at very low levels in both locations, and there were no statistically significant differences in the expression levels between ovarian and non-ovarian ETs, even though the expression of Ki-67 and Aurora B kinase in the glandular component seemed to be lower in ovarian than in non-ovarian ETs (P ¼ 0.353 and P ¼ 0.204).
Discussion
Aurora kinase
Aberrations in the regulation of endometrial physiology may lead to the development of endometriosis, but the etiopathogenic roles of altered cell proliferation, cell cycle control and genomic instability remain controversial. Therefore, we decided to investigate the possible role of Aurora kinases, which have recently emerged as key mitotic regulators for genome stability and are frequently overexpressed in human tumours (Fu et al., 2007) .
The important role of Aurora kinases in mitosis and chromosome segregation explains their high expression levels in many human tumours (Cohen et al., 2009) , such as endometrial cancer (Kurai et al., 2005) . Additionally, according to the literature, there seems to be an increasing expression gradient of Aurora kinases from secretory endometrium to endometrial hyperplasia and then to proliferative endometrium and finally endometrial cancer (Kurai et al., 2005) . In our analysis, we first considered Aurora A and B expression in ETs and compared these expression levels with those in healthy endometrium. In particular, we demonstrated very low expression of Aurora A and B in the ET resembling that in the secretory endometrium, in both the glandular and stromal components (Table II) . We also showed the expression of these proteins is higher in the proliferative endometrium than in the secretory endometrium.
If we consider that Aurora B and Aurora A kinases were generally expressed at a low level (Table III) , the growth and survival of endometrial tissue outside the uterus cannot be solely explained by the increased cellular proliferation related to this pathway. On the other hand, we interestingly found that Aurora B kinase was significantly in the subset of samples that express Aurora A Kinase. In the row under the labels are reported median and IQR values of H-scores. The P-value, at the end of the row, refers to Kruskal-Wallis test ( §), while the P-values (*) reported in the plot area refer to Wilcoxon test. These P-values show the significant differences in H-score values of cytoplasm between ETs and proliferative endometrium. (b -e) show immunostaining of Aurora A kinase in ovarian and non-ovarian ETs and in proliferative and secretory endometrium.
Expression patterns of Aurora A and B kinases Figure 3 Expression of Aurora B kinase, and Ki-67 in ovarian ETs and other locations. In the graphic (a), the barplots show the prevalence of values higher than the median value of the related distribution. We considered the H-scores for Aurora B kinase in glandular and stromal components and for Ki-67 (*) the percentage of positive cells per slide. The odds ratios (OR) and P-values, at the top of the bars, refer to a multivariate logistic regression analysis where the dependent variable is the prevalence of values higher than the median value of the related distribution (the analysis is corrected for the women age). (b -e) show nuclear immunostaining of Aurora B kinase, and (f-i) of Ki-67 in ovarian and non-ovarian ETs and proliferative and secretory endometrium. In healthy endometrium, Aurora B kinase and Ki-67 were diffusely expressed in the proliferative phase (d and h) and downregulated in the secretory phase (e and i). The expression levels of Aurora B kinase, Ki-67 in ovarian ET (b and f) were minimal, similar to those of secretory endometrium. In non-ovarian ET (c and g), Aurora B kinase and Ki-67 immunostaining levels were higher than in ovarian ET.
higher in non-ovarian than in ovarian endometriosis. These data could be explained by the presence of a wider proliferative pool of cells in non-ovarian than ovarian ETs. In addition, this is supported by the higher prevalence of positive Ki-67 marked cells in non-ovarian than ovarian ETs. This hypothesis did not explain the similar expression pattern of Aurora A kinase between ovarian and non-ovarian ETs. Therefore, different expression levels of Aurora B and A might be explained considering that only Aurora B kinase associates with inner centromere protein (INCENP), borealin and survivin, which have a key role in cell cycle control and apoptosis (Lens et al., 2010; Musacchio, 2010) .
In addition, when considering only the positive cells, Aurora A expression was significantly higher in the cytoplasm of the glandular cells of ovarian and non-ovarian ETs than in those of the proliferative endometrium (Fig. 2) . Aurora A expression was also significantly higher in the stromal cytoplasm of non-ovarian ETs than in the ovarian ETs and the proliferative endometrium. This high cytoplasmic protein expression could indicate a more aggressive disease or could be related to a subtype of endometriosis characterized by genomic instability. In particular, of the 139 patients for whom we had available follow-up imaging (transvaginal sonography or magnetic resonance), at least 2 years after the intervention, 19% had an image suggesting endometriosis relapse. Among the patients with cytoplasmic expression of Aurora A kinase that was higher than that in the proliferative endometrium, the diagnosed relapse prevalence was 67%. These analyses were not confirmed by surgery, and for this reason, false negative and false positives could limit the validity of this observation. Moreover, we have no follow-up data on malignancies in these patients.
Recently, other authors have demonstrated that Aurora A kinase is a negative prognostic factor in patients with endometrioid ovarian carcinoma. Particularly Aurora A kinase is expressed in about 48% of patients with endometrioid ovarian carcinoma and it is clearly associated with shorter overall and disease free survival durations (Yang et al., 2011) . Given that a possible direct association with endometriosis has been previously suggested (Jiang et al., 1998; Nissenblatt, 2011) , we speculated that only endometriotic lesions at high risk of malignant degeneration showed high levels of Aurora A kinase in stromal and glandular cytoplasmatic component. It would be interesting to further validate our hypothesis with prospective studies in order to understand if evaluation of Aurora A kinase in endometriotic samples could become a trusty prognostic factor in term of risk of disease relapse and malignant degeneration.
Antigen Ki-67
Ki-67 has been widely used to assess the cellular proliferative status in a variety of neoplastic conditions, and it has already been reported that Ki-67 is expressed at a lower level in ETs than in proliferative endometrium (Table III) (Suzuki et al., 2010) .
We also observed lower expression of Ki-67 in ovarian ETs than in non-ovarian ETs and confirmed the correlation of Ki-67 expression with the expression of Aurora A and B (Kurai et al., 2005) . Therefore, these two kinases are expressed in proliferative endometriotic cells.
Estrogen and progesterone receptors
In eutopic endometrium, the expression levels of the estrogen and progesterone receptors vary predictably with the phase of the menstrual cycle; the estrogen receptor is less strongly expressed in both glandular and stromal cells and the progesterone receptor is strongly expressed in the stromal component during the secretory phase. This cyclic change has not been observed in ET. Hormone receptors were expressed at a lower level in the ectopic than in the eutopic endometrium, and in particular, they were expressed at a lower level in ovarian ETs than in non-ovarian ETs and proliferative and secretory endometrium. Therefore, our study confirms the previous literature in this field, validating our TMA model (Bergqvist et al., 1993; Nisolle et al., 1997; Suzuki et al., 2010) .
Among the published English-language studies about hormone receptor expression included in MEDLINE, even the larger series consisted of fewer than 40 women affected by endometriosis with ovarian and non-ovarian locations (Bergqvist et al., 1993; Nisolle et al., 1997; Kamat et al., 2004) . Moreover, only one previous study about TMA techniques applied to endometriosis was found in MEDLINE (Kamat et al., 2004) . In our study, we confirmed the validity of the TMA technique to study endometriosis with 194 women affected by ovarian and non-ovarian endometriosis and 28 controls. Furthermore, in our work, we point out some aspects not deeply explored by other studies. In particular, ovarian ETs presented a significantly lower expression of hormone receptors than non-ovarian ETs. Moreover, considering the gland H-score/stroma H-score ratio, the differences between ovarian and non-ovarian endometriosis are more evident because the estrogen gland H-score/stroma H-score ratio was inverted in ovarian ETs relative to non-ovarian ETs. Moreover, our findings suggest a similar behaviour of ovarian ETs to secretory endometrium, supported by the progesterone gland H-score/stroma H-score ratios (Fig. 1) , which were lower than in non-ovarian ETs and proliferative endometrium.
The decreased expression of proliferation markers and hormone receptors in ovarian ETs may have different explanations.
Some authors suggest a higher amount of non-endometrial tissue in ovarian ETs. To exclude the possible bias due to different endometrial tissue proportions in the different endometriosis locations, we evaluated the percentage of positive endometrial cells. Using this method, we demonstrated a significantly higher level of expression of hormone receptors in non-ovarian than in ovarian ETs.
Another possible etiopathogenic hypothesis is that there is an influence of the peritoneal fluid microenvironment on the different endometriosis locations. Finally, we suggest a third hypothesis, which will be presented in the following paragraph.
Paracrine hypothesis
Paracrine communication in the ovary is essential for the follicular cycle and hormone production (Yada et al., 1999) . In our opinion, the lower expression of hormone receptors in ovarian ETs may be due to the down-regulation of these receptors in the ovarian environment, whereas eutopic endometrium and non-ovarian ETs are only exposed to the circulating steroids from the blood. The absence of this paracrine effect in non-ovarian ETs leads to levels of hormone receptor expression and cell proliferation that are intermediate between those of ovarian ET and proliferative endometrium (Table II) .
Our hypothesis is also support by the fact levonorgestrel-releasing intrauterine systems reduce both cell proliferation and the expression of hormone receptors in ETs (Gomes et al., 2009) . This paracrine hypothesis is also supported by the comparison between the ovarian and non-ovarian locations in the subgroup of patients for which core biopsies were available for multiple endometriosis locations. Comparison of these specimens revealed significantly higher hormone receptor expression in the glandular component in the non-ovarian than in the ovarian ETs.
Our hypothesis is based on data obtained from a TMA study, and future in vivo studies could further validate our hypothesis.
Pro et contra
Despite the retrospective nature of our study, the large number of cases reinforces our data analysis. Our sample comparison would have been more accurate if the samples of healthy endometrium and ET had come from the same patient.
We also have to point out the significant age difference between cases and controls; however, the stratified analysis showed the same level of significance in the expression pattern differences as in the whole population. This demonstrates that the difference is irrelevant in terms of the study's results.
Conclusions
In conclusion, considering the very low expression levels of the Aurora A and B kinases in the majority of endometriosis core biopsies, the growth and survival of endometrial tissue outside the uterus cannot be explained by increased cellular proliferation related to this pathway. However, Aurora A Kinase was interestingly over-expressed in a subset of patients with endometriosis. In general, the expression pattern of Aurora A and B kinases, Ki-67, and the estrogen and progesterone receptors in ETs was more similar to the expression pattern of secretory endometrium than that of proliferative endometrium. Moreover, there was an evident difference between ovarian and nonovarian ETs, which may be explained by the influence of ovarian steroids on the ovarian endometrial tissue, whereby ectopic endometrium in the ovary could undergo receptor down-regulation under the paracrine effect of ovarian hormones.
